These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15072611)

  • 1. New developments with bortezomib in treating multiple myeloma.
    Reddy GK
    Clin Lymphoma; 2004 Mar; 4(4):215-6. PubMed ID: 15072611
    [No Abstract]   [Full Text] [Related]  

  • 2. [Bortezomib].
    Simons S; Scheulen ME; Jaehde U
    Dtsch Med Wochenschr; 2006 Feb; 131(5):214-8. PubMed ID: 16440269
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
    Richardson P
    Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy.
    Driscoll JJ; Burris J; Annunziata CM
    Am J Ther; 2012 Mar; 19(2):133-44. PubMed ID: 21248621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the proteasome inhibitor bortezomib in hematologic malignancies.
    Goy A; Gilles F
    Clin Lymphoma; 2004 Mar; 4(4):230-7. PubMed ID: 15072615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review. Clinical pharmacokinetics of bortezomib.
    Levêque D; Carvalho MC; Maloisel F
    In Vivo; 2007; 21(2):273-8. PubMed ID: 17436576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematologic malignancies: from clinical science to clinical practice - 2nd European Congress.
    Ferreri AJ
    IDrugs; 2006 Apr; 9(4):242-6. PubMed ID: 16596473
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical study of bortezomib in the treatment of multiple myeloma patients with renal failure].
    Cao ZG; Liu M; Zhou HW
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jan; 34(1):74-5. PubMed ID: 23597473
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful bone reconstruction after bortezomib therapy in a myeloma patient.
    Tanaka T; Yamasaki R; Omura H; Hino N
    Int J Hematol; 2011 Sep; 94(3):221. PubMed ID: 21861100
    [No Abstract]   [Full Text] [Related]  

  • 10. Bortezomib in multiple myeloma.
    Meisler AI
    N Engl J Med; 2003 Sep; 349(13):1287-8; author reply 1287-8. PubMed ID: 14510013
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
    Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib-related colon mucositis in a multiple myeloma patient.
    Siniscalchi A; Tendas A; Ales M; Fratoni S; Cupelli L; Dentamaro T; Scaramucci L; Giovannini M; Caravita T; Santeusanio G; Niscola P; de Fabritiis P
    Support Care Cancer; 2009 Apr; 17(4):325-7. PubMed ID: 19172306
    [No Abstract]   [Full Text] [Related]  

  • 13. Proteasome inhibitor for treatment of multiple myeloma.
    Ahmad K
    Lancet Oncol; 2005 Aug; 6(8):546. PubMed ID: 16094754
    [No Abstract]   [Full Text] [Related]  

  • 14. Experiences with bortezomib in multiple myeloma - from Phase II studies to daily practice.
    Schmitt S; Bertsch U; Goldschmidt H
    Int J Clin Pharmacol Ther; 2010 Jul; 48(7):494-6. PubMed ID: 20557858
    [No Abstract]   [Full Text] [Related]  

  • 15. Discovery, Development, and clinical applications of bortezomib.
    Jung L; Holle L; Dalton WS
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.
    Zeng Z; Lin J; Chen J
    Ann Hematol; 2013 Jul; 92(7):935-43. PubMed ID: 23455401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?
    San Miguel JF
    Haematologica; 2014 Jan; 99(1):5-6. PubMed ID: 24425688
    [No Abstract]   [Full Text] [Related]  

  • 18. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
    Caravita T; de Fabritiis P; Palumbo A; Amadori S; Boccadoro M
    Nat Clin Pract Oncol; 2006 Jul; 3(7):374-87. PubMed ID: 16826218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
    Waterman GN; Yellin O; Swift RA; Mapes R; Eades B; Ackerman E; Berenson JR
    Ann Hematol; 2011 Feb; 90(2):193-200. PubMed ID: 20809423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens.
    Roussou M; Kastritis E; Migkou M; Psimenou E; Grapsa I; Matsouka C; Barmparousi D; Terpos E; Dimopoulos MA
    Leuk Lymphoma; 2008 May; 49(5):890-5. PubMed ID: 18464107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.